EPNextS Group and Frontage Laboratories, Inc. Announce Collaboration in Early Phase Clinical Trials in the United States to Improve "Drug Lag" and "Drug Loss" Issues in Japan
- None.
- None.
EPNextS Group and Frontage intend to leverage EPNextS Group's expertise in clinical trial solutions and Frontage's extensive experience in early-phase drug development and clinical research services, to overcome these challenges and drive positive change in the pharmaceutical landscape.
"We are excited to join forces with Frontage to address the critical issues of drug lag and drug loss in
EPS Corporation, led by Takehisa Yamada, Representative Director and President, is a wholly owned subsidiary of EPNextS. EPS and Frontage intend to conduct collaborative business development activities in
Frontage brings a wealth of experience in early-phase clinical research, including bioanalytical services, clinical pharmacology, and clinical operations. Frontage services are expected to include clinical trial execution, data management, biostatistical programming, pharmacokinetic analyses, and medical writing.
"We are pleased announce this collaboration with EPNextS Group to address the pressing challenges facing the Japanese pharmaceutical industry," said Abdul Mutlib, CEO of Frontage. "Together, we will leverage our collective expertise to accelerate the development and commercialization of new therapies, ultimately benefiting patients in
The collaboration between EPNextS Group and Frontage represents a significant step forward in addressing the complexities of drug development and regulatory processes in
About EPS
[About EPNextS Group] EPNextS Group is a leading provider of comprehensive clinical trial solutions, offering a range of services to support pharmaceutical and biotechnology companies in accelerating drug development. With a focus on innovation and efficiency, EPNextS Group is committed to advancing clinical research and improving patient access to life-saving therapies. https://www.epnexts.co.jp/event/en.php
[About EPS Corporation] EPS launched its business in 1991 as a Top Tier CRO to comprehensively support clinical studies with a focus on clinical trials and post marketing surveillance. The company proposes new models to satisfy customers' needs by leveraging its data science expertise and digital technology, cultivated through its extensive track record. These service offerings are anchored in its Trial GATE concept, which acts as the gateway for all clinical trial functions. https://www.epsi-global.com/index.html; https://www.eps.co.jp/en/
[About EP-SOGO Co., Ltd.] EP-SOGO started its SMO business in 1999, and currently has contracts with approximately 7,000 Investigators' sites (medical institutions) and handles clinical trial operations at these sites so clinical trials can be conducted in accordance with ICH-GCP and relevant regulations. Celebrating its 25th anniversary this year as a milestone for a new beginning, the company will change its name to "EPLink Co., Ltd." on April 1, 2024. With a renewed commitment, EPLink aims to continuously create new values that contribute to the further improvement of the clinical trial environment and propose the best solutions. https://www.epsogo.co.jp/en/
About Frontage (www.frontagelab.com)
Frontage Holdings Corp (1521.HK), together with its wholly owned subsidiary Frontage Laboratories, Inc., is a global Contract Research Organization (CRO) which provides integrated, science-driven, product development services from drug discovery to late phase clinical process to enable biopharmaceutical companies to achieve their development goals. Comprehensive services include drug metabolism and pharmacokinetics, analytical testing and formulation development, preclinical and clinical trial material manufacturing, bioanalysis, preclinical safety and toxicology assessment and early phase clinical studies. Frontage has enabled many biotechnology companies and leading pharmaceutical companies of varying sizes to advance a myriad of new molecules through development and to successfully file global regulatory submissions. For more details visit: www.frontagelab.com
Contact: Debra Santolini, (908) 872-8092, dsantolini@frontagelab.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/epnexts-group-and-frontage-laboratories-inc-announce-collaboration-in-early-phase-clinical-trials-in-the-united-states-to-improve-drug-lag-and-drug-loss-issues-in-japan-302099451.html
SOURCE Frontage Laboratories, Inc.
FAQ
What is the collaboration about between EPNextS Group and Frontage Laboratories?
Who are the key figures mentioned in the press release from EPNextS Group and Frontage Laboratories?
What expertise does EPNextS Group bring to the collaboration?
What services does Frontage Laboratories offer in the collaboration?